0.31%
-9.04%
-21.27%
-32.78%
-44.48%
-67.54%
-67.01%
AI Spotlight on OABI
Company Description
OmniAb, Inc., a biotechnology company, provides therapeutic antibody discovery technologies in the United States.The company's discovery platform provides industry partners access to the diverse antibody repertoires and screening technologies to enable discovery of next-generation therapeutics.Its OmniAb platform is the biological intelligence of proprietary transgenic animals, including OmniRat, OmniChicken, and OmniMouse that have been genetically modified to generate antibodies with human sequences to facilitate development of human therapeutic candidates.
The company's OmniFlic (transgenic rat) and OmniClic (transgenic chicken) address industry needs for bispecific antibody applications though a common light chain approach, and OmniTaur that features unique structural attributes of cow antibodies for complex targets.The company was founded in 2012 and is headquartered in Emeryville, California.
Market Data
| Last Price | 3.22 |
| Change Percentage | 0.31% |
| Open | 3.19 |
| Previous Close | 3.21 |
| Market Cap ( Millions) | 390 |
| Volume | 492570 |
| Year High | 6.55 |
| Year Low | 3.1 |
| M A 50 | 3.64 |
| M A 200 | 4.15 |
Financial Ratios
| FCF Yield | -27.87% |
| Dividend Yield | 0.00% |
| ROE | -20.97% |
| Debt / Equity | 8.17% |
| Net Debt / EBIDTA | 5.43% |
| Price To Book | 1.13 |
| Price Earnings Ratio | -5.23 |
| Price To FCF | -3.59 |
| Price To sales | 19.09 |
| EV / EBITDA | -6.17 |
News
- Jan -31 - Kuehn Law Encourages Investors of OmniAb, Inc. to Contact Law Firm
- Dec -16 - OmniAb Technologies Featured in Two Presentations at the 2024 Antibody Engineering & Therapeutics Conference
- Nov -13 - OmniAb, Inc. (OABI) Q3 2024 Earnings Call Transcript
- Nov -13 - OmniAb, Inc. (OABI) Reports Q3 Loss, Lags Revenue Estimates
- Aug -10 - OmniAb, Inc. (OABI) Q2 2024 Earnings Call Transcript
- Aug -06 - Long Assets On Path To Creating Significant Value, Shorting Remains Very Challenging
- Jun -03 - OmniAb Announces Publication of Scientific Paper on Heavy Chain-Only Single-Domain Antibody Chicken Platform in the Journal of Immunology
- May -20 - OmniAb to Participate in the Jefferies Global Healthcare Conference
- May -15 - OmniAb Presents High-Throughput Single B-cell Screening xPloration® Data at the 20th Annual PEGS Boston Summit
- May -10 - OmniAb, Inc. (OABI) Q1 2024 Earnings Call Transcript
- May -09 - OmniAb Reports First Quarter 2024 Financial Results and Business Highlights
- May -01 - OmniAb to Participate in Five Investor Conferences in May
- Apr -22 - OmniAb to Report First Quarter 2024 Financial Results on May 9
- Apr -15 - Tharimmune Announces Scientific Advisory Board to Drive Clinical-Stage Lead in Chronic Liver Disease and Early-Stage Tunable Knob Domains for Generating Antibody Drug Conjugate (ADC) Biotherapeutics
- Mar -20 - OmniAb, Inc. (OABI) Q4 2023 Earnings Call Transcript
- Mar -20 - OmniAb Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights
- Feb -28 - OmniAb, Inc. (OABI) Soars 10.5%: Is Further Upside Left in the Stock?
- Feb -26 - OmniAb to Report Fourth Quarter 2023 Financial Results on March 20
- Dec -15 - Mighty Minis: 7 Small-Cap Stocks That Punch Above Their Weight
- Dec -14 - OmniAb Presents New Scientific Data on its OmnidAb™ Platform at the 2023 Antibody Engineering & Therapeutics Conference
Business Breakdown
Expected Mid-Term Growth
Segment n°1 -> License and Milestone
Expected Growth : 10.27 %
What the company do ?
OmniAb, Inc.'s License grants access to its antibody discovery platform, while Milestone refers to the specific goals and deadlines in the collaboration agreement.
Why we expect these perspectives ?
OmniAb, Inc.'s 10.27% growth in License and Milestone revenue is driven by increasing adoption of its antibody discovery platform, expansion into new therapeutic areas, and strategic partnerships. Additionally, the company's growing pipeline of partnered programs and successful milestone achievements contribute to this growth.
Segment n°2 -> Service
Expected Growth : 10.27 %
What the company do ?
OmniAb, Inc.'s Service provides a platform for antibody discovery, offering a comprehensive solution for identifying and optimizing therapeutic antibodies.
Why we expect these perspectives ?
OmniAb, Inc.'s 10.27% growth is driven by increasing demand for antibody discovery services, expansion into new therapeutic areas, and strategic partnerships. Additionally, advancements in AI-powered antibody optimization and proprietary platform enhancements are contributing to the company's growth momentum.
Segment n°3 -> Royalty
Expected Growth : 9.27 %
What the company do ?
OmniAb, Inc.'s Royalty refers to the payment made to the company for the use of its proprietary antibody discovery platform, which enables the development of novel therapeutic antibodies.
Why we expect these perspectives ?
The 9.27% growth in Royalty from OmniAb, Inc. is driven by increasing demand for antibody-based therapeutics, successful partnerships with biotech companies, and expansion into new markets. Additionally, OmniAb's proprietary technology and high-quality antibody libraries have enabled the company to secure lucrative licensing agreements, contributing to the robust growth.
Omniab, Inc. Products
| Product Range | What is it ? |
|---|---|
| OmniRat-G3 | A high-affinity, fully human IgG1 monoclonal antibody that targets a specific epitope on the human CD38 antigen |
| OmniAb-Vec | A proprietary vector technology that enables the efficient generation of fully human monoclonal antibodies |
| OmniRat-G4 | A high-affinity, fully human IgG1 monoclonal antibody that targets a specific epitope on the human PD-1 antigen |
| OmniChicken | A proprietary chicken-based platform for the generation of high-affinity, fully human monoclonal antibodies |
| OmniMouse | A proprietary mouse-based platform for the generation of high-affinity, fully human monoclonal antibodies |
OmniAb, Inc.'s Porter Forces
Threat Of Substitutes
OmniAb, Inc. has a moderate threat of substitutes due to the availability of alternative products in the market.
Bargaining Power Of Customers
OmniAb, Inc. has a high bargaining power of customers due to the presence of large and influential buyers in the market.
Bargaining Power Of Suppliers
OmniAb, Inc. has a low bargaining power of suppliers due to the presence of multiple suppliers in the market.
Threat Of New Entrants
OmniAb, Inc. has a moderate threat of new entrants due to the presence of barriers to entry and the need for significant investment in research and development.
Intensity Of Rivalry
OmniAb, Inc. operates in a highly competitive market with many established players, leading to a high intensity of rivalry.
Capital Structure
| Value | |
|---|---|
| Debt Weight | 7.51% |
| Debt Cost | 3.95% |
| Equity Weight | 92.49% |
| Equity Cost | 3.95% |
| WACC | 3.95% |
| Leverage | 8.13% |
OmniAb, Inc. : Quality Control
OmniAb, Inc. passed 4 out of 9 key points:
Historical Valuation
Price/Earnings Ratio
Margin Valuation
Peers Valuation
Competitors
| Company | Rational |
|---|---|
| SYRS | Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatments for cancer and monogenic diseases, and building a pipeline of gene control medicines. The company's lead product candidates … |
| XERS | Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies for patient populations in endocrinology, neurology, and gastroenterology. The company markets Gvoke, a ready-to-use liquid glucagon for … |
| MNKD | MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled … |
| KYMR | Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It … |
| ATNM | Actinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant (BMT) or a type of cellular therapy, and for other adoptive cell therapies. … |
Peers Metrics
DCF BETA
Expected Cash-Flows
Scoring Insights
Peers Group Analysis
🥇
Xeris Biopharma
A-Score
1-Year Total Return ->
🥈
MannKind
A-Score
1-Year Total Return ->
🥉
Kymera Therapeutics
A-Score
1-Year Total Return ->
4
OmniAb
A-Score
1-Year Total Return ->
5
Syros Pharmaceuticals
A-Score
1-Year Total Return ->
6
